SLC5A2 and type 2 diabetes mellitus: Although SGLT2 inhibitors provide cardiorenal benefits independently of glucose- and weight-reducing effects, lifestyle modification and weight loss remain the most important and fundamental therapy for patients with T2DM [20,21,22].